Advertisement
Systematic Review|Articles in Press, 100896

Meta-analysis of the diagnostic and clinical utility of exome and genome sequencing in pediatric and adult patients with rare diseases across diverse populations

Open AccessPublished:May 13, 2023DOI:https://doi.org/10.1016/j.gim.2023.100896
Meta-analysis of the diagnostic and clinical utility of exome and genome sequencing in pediatric and adult patients with rare diseases across diverse populations
Previous ArticleCommitting to Genomic Answers for All Kids: Evaluating Inequity in Genomic Research Enrollment
Next ArticleBiallelic variants in Ribonuclease Inhibitor (RNH1), an inflammasome modulator, are associated with a distinctive subtype of acute necrotizing encephalopathy
      This paper is only available as a PDF. To read, Please Download here.

      Abstract

      Purpose

      This meta-analysis aims to compare the diagnostic and clinical utility of whole-exome sequencing (WES) versus whole-genome sequencing (WGS) in pediatric and adult patients with rare diseases across diverse populations.

      Methods

      A meta-analysis was conducted to identify studies from 2011-2021.

      Results

      One-hundred-and-sixty-one studies across 31 countries/regions were eligible, featuring 50,417 probands of diverse populations. Diagnostic rates of WES (0.38, 95% CI 0.36-0.40) and WGS (0.34, 95% CI 0.30-0.38) were similar (p=0.1). Within-cohort comparison illustrated a 1.2 times odds of diagnosis by WGS over WES (95% CI 0.79-1.83, p=0.38). WGS studies discovered a higher range of novel genes than WES studies, yet the rate of variant of unknown significance (VUS) did not differ (p=0.78). Among high-quality studies, clinical utility of WGS (0.77, 95% CI 0.64-0.90) was higher than WES (0.44, 95% CI 0.30-0.58) (p<0.01).

      Conclusion

      This meta-analysis provides an important update to demonstrate the similar diagnostic rates between WES and WGS and the higher clinical utility of WGS over WES. With the newly published recommendations for clinical interpretation of variants found in non-coding regions of the genome and the trend of decreasing VUS and WGS cost, it is expected that WGS will be more widely used in clinical settings.

      Keywords

      Article info

      Publication history

      Accepted: May 10, 2023
      Received in revised form: May 7, 2023
      Received: December 13, 2022

      Publication stage

      In Press Accepted Manuscript

      Identification

      DOI: https://doi.org/10.1016/j.gim.2023.100896

      Copyright

      © 2023 The Authors. Published by Elsevier Inc. on behalf of American College of Medical Genetics and Genomics.

      User license

      Creative Commons Attribution – NonCommercial – NoDerivs (CC BY-NC-ND 4.0) |
      How you can reuse Information Icon
      Creative Commons Attribution – NonCommercial – NoDerivs (CC BY-NC-ND 4.0)

      Permitted

      For non-commercial purposes:

      • Read, print & download
      • Redistribute or republish the final article
      • Text & data mine
      • Translate the article (private use only, not for distribution)
      • Reuse portions or extracts from the article in other works

      Not Permitted

      • Sell or re-use for commercial purposes
      • Distribute translations or adaptations of the article

      Elsevier's open access license policy

      ScienceDirect

      Access this article on ScienceDirect

      The content on this site is intended for healthcare professionals.


      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the Cookie Preference Center for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties.


      RELX